The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28098449 |
48 |
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation. |
Universidade De Lisboa |
| 28045524 |
38 |
Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes. |
Lexicon Pharmaceuticals |
| 27075813 |
49 |
N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors. |
National Health Research Institutes |
| 24881566 |
140 |
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). |
Glaxosmithkline |
| 24842618 |
56 |
The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties. |
Amri |
| 24556379 |
34 |
Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors. |
Csir-Indian Institute of Chemical Technology |
| 24456245 |
24 |
Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes. |
Fudan University |
| 24900773 |
14 |
Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes. |
Mitsubishi Tanabe Pharma |
| 24071445 |
30 |
Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors. |
National Taiwan University |
| 23999047 |
9 |
N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors. |
Mitsubishi Tanabe Pharma |
| 23809172 |
9 |
C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors. |
Mitsubishi Tanabe Pharma |
| 23273606 |
64 |
Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-ylß-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1). |
Kissei Pharmaceutical |
| 22889351 |
40 |
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. |
Chugai Pharmaceutical |
| 23062824 |
72 |
Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-ylß-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia. |
Kissei Pharmaceutical |
| 22818040 |
26 |
Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors. |
National Health Research Institutes |
| 22652255 |
50 |
C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. |
Chugai Pharmaceutical |
| 21128592 |
51 |
Discovery of novel N-ß-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. |
Taiwan National Health Research Institutes |
| 19785435 |
58 |
Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. |
Lexicon Pharmaceuticals |
| 10794686 |
19 |
Probing the conformation of the sugar transport inhibitor phlorizin by 2D-NMR, molecular dynamics studies, and pharmacophore analysis. |
Max-Planck-Institut F£R Molekulare Physiologie |
| 21873071 |
34 |
5a-Carba-ß-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. |
Chugai Pharmaceutical |
| 21737266 |
43 |
C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. |
Chinese Academy of Sciences |
| 21565497 |
38 |
Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors. |
Amgen |
| 21449606 |
15 |
Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. |
Pfizer |
| 21398124 |
62 |
Discovery of non-glucoside SGLT2 inhibitors. |
Amgen |
| 20690635 |
12 |
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. |
Mitsubishi Tanabe Pharma |
| 20576578 |
36 |
ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. |
Chinese Academy of Sciences |
| 20192242 |
4 |
Gneyulins A and B, stilbene trimers, and noidesols A and B, dihydroflavonol-C-glucosides, from the bark of Gnetum gnemonoides. |
Hoshi University |
| 20302302 |
40 |
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. |
Taisho Pharmaceutical |
| 20149653 |
36 |
C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization. |
Pfizer |
| 20189404 |
28 |
Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. |
Hoshi University |
| 19896374 |
53 |
Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. |
Chinese Academy of Sciences |
| 19700318 |
6 |
O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. |
Chinese Academy of Sciences |
| 17686765 |
4 |
Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. |
University WüRzburg |
| 17374486 |
6 |
Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. |
Nippon Suisan Kaisha |
| 16380256 |
35 |
Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2. |
Johnson & Johnson Pharmaceutical Research and Development |
| 16198559 |
17 |
Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1. |
Johnson & Johnson Pharmaceutical Research and Development |
| 15380212 |
46 |
Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors. |
Johnson & Johnson Pharmaceutical Research and Development |
| 32008883 |
41 |
Anti-diabetic drugs recent approaches and advancements. |
Mizoram University |
| 31325786 |
48 |
Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. |
Chinese Academy of Sciences |
| 31930920 |
69 |
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. |
Terns Pharmaceuticals |
| 31630053 |
21 |
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. |
Jamia Hamdard |
| 30579799 |
41 |
Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment. |
Taisho Pharmaceutical |
| 30297284 |
35 |
Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes. |
Taisho Pharmaceutical |
| 30268701 |
25 |
Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors. |
Janssen Research & Development |
| 29954682 |
14 |
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents. |
Guangdong Pharmaceutical University |
| 29523385 |
34 |
Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors. |
Janssen Research and Development |
| 29216560 |
39 |
Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2. |
National Health Research Institutes |
| 28447791 |
30 |
Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes. |
Haisco Pharmaceuticals Group |
| 34528437 |
44 |
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies. |
Purdue University |
| 12130733 |
17 |
Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. |
University of Kentucky |
| 2841449 |
9 |
Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor. |
Merck Sharp & Dohme Research Laboratories |
| 7490733 |
59 |
Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine. |
Boehringer Ingelheim Pharmaceuticals |
Search and Browse
